Ketamine-Assisted Psychotherapy Alters DNA Methylation in MDD Patients

Ketamine-Assisted Psychotherapy Linked to DNA Methylation Changes in Depression

Recent research published on October 15, 2026, provides the first longitudinal evidence that ketamine-assisted psychotherapy (KAP) for major depressive disorder (MDD) is associated with measurable changes in peripheral DNA methylation. In a small cohort of 10 adults with MDD, three sessions of intranasal racemic ketamine, administered within a structured psychotherapy protocol, led to significant reductions in depressive symptoms as measured by the Beck Depression Inventory–II. Alongside clinical improvement, the study identified a distinct set of DNA methylation changes in buccal (cheek cell) samples, suggesting that rapid-acting antidepressant interventions may trigger molecular adaptations detectable outside the brain.

Mechanistic Insights: Notch Signaling Pathway Implicated

The study used the Illumina MethylationEPIC v2.0 BeadChip to interrogate over 800,000 CpG loci, ultimately identifying 962 loci with significant methylation changes post-treatment. Exploratory enrichment analysis revealed that a subset of these loci clustered around the Notch signaling pathway, specifically involving genes such as NOTCH1, DLL1, and ADAM17. The Notch pathway is known to regulate cell differentiation and neuroplasticity, processes relevant to mood disorders and antidepressant response. While these findings do not establish causality or confirm brain-specific effects, they provide a plausible biological framework for how ketamine might exert sustained antidepressant action beyond its acute pharmacological effects.

Notably, the study's use of repeated pre-treatment assessments (T1, T2) and a post-treatment assessment (T3) allowed for the filtering of methylation changes that exceeded natural pre-treatment fluctuations. This methodological step is rarely highlighted in similar studies but is crucial for distinguishing treatment-related effects from baseline variability—a non-obvious decision criterion that strengthens the validity of the findings, even in a small sample.

Policy and Research Implications: Toward Biomarker Development

These results open new avenues for biomarker discovery in psychedelic and rapid-acting antidepressant research. If replicated in larger, independent cohorts, peripheral DNA methylation signatures could serve as objective markers of treatment response, aiding both clinical trials and personalized psychiatry. This is particularly relevant as regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly seek biological endpoints to supplement subjective symptom reports in psychiatric drug development.

However, the study’s sample size (n=10) and lack of a control group mean that immediate translation into clinical practice or regulatory guidance is not warranted. The findings instead provide a rationale for larger, controlled studies that could validate methylation changes as predictive or mechanistic biomarkers. For research sponsors and trial designers, the study underscores the importance of integrating molecular endpoints into future KAP and psychedelic therapy protocols, potentially accelerating the path toward precision psychiatry.

Risks, Limitations, and Unknowns

The main limitations of this study are its small sample size, absence of a placebo or active control group, and reliance on peripheral tissue (buccal cells) rather than direct brain measures. Peripheral methylation changes may not fully reflect central nervous system processes, and the observed associations do not establish causality between methylation changes and clinical improvement. Additionally, the methylation signature has not been independently replicated, and the specific functional consequences of altered Notch pathway methylation remain to be elucidated.

There is also a risk that premature enthusiasm for biomarker discovery could outpace the underlying science, leading to overinterpretation or misapplication in clinical or legal settings. As psychedelic-assisted therapies move toward broader adoption, careful attention to methodological rigor and replication will be essential to avoid false positives and ensure patient safety.

Looking Forward: Next Steps for Research and Practice

Future studies should prioritize larger, randomized controlled trials with diverse populations and multiple tissue types to confirm and extend these findings. Integration of multi-omic data (e.g., transcriptomics, proteomics) and direct brain imaging could clarify the causal pathways linking ketamine, DNA methylation, and antidepressant response. For clinicians and policymakers, the current evidence is best viewed as a promising but preliminary step toward understanding the molecular underpinnings of psychedelic and rapid-acting antidepressant interventions.

As the field matures, robust biomarkers could facilitate more targeted and effective treatments for MDD and related disorders, but careful validation and regulatory oversight will be critical to ensure that scientific advances translate into real-world benefit.

How we research: This article was written and reviewed by Dr. Alex S. Meyer, PhD (neuroscience), on 2026-10-20. Primary source: OpenAlex study record. Data and claims were verified against the original publication and FDA biomarker guidance.